Caseware UK (AP4) 2023.0.135 2023.0.135 2024-06-302024-06-3022023-07-01falseNo description of principal activity2truetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 07673770 2023-07-01 2024-06-30 07673770 2022-07-01 2023-06-30 07673770 2024-06-30 07673770 2023-06-30 07673770 2022-07-01 07673770 c:Director1 2023-07-01 2024-06-30 07673770 d:CurrentFinancialInstruments 2024-06-30 07673770 d:CurrentFinancialInstruments 2023-06-30 07673770 d:CurrentFinancialInstruments d:WithinOneYear 2024-06-30 07673770 d:CurrentFinancialInstruments d:WithinOneYear 2023-06-30 07673770 d:ShareCapital 2024-06-30 07673770 d:ShareCapital 2023-06-30 07673770 d:ShareCapital 2022-07-01 07673770 d:CapitalRedemptionReserve 2024-06-30 07673770 d:CapitalRedemptionReserve 2023-06-30 07673770 d:CapitalRedemptionReserve 2022-07-01 07673770 d:RetainedEarningsAccumulatedLosses 2023-07-01 2024-06-30 07673770 d:RetainedEarningsAccumulatedLosses 2024-06-30 07673770 d:RetainedEarningsAccumulatedLosses 2022-07-01 2023-06-30 07673770 d:RetainedEarningsAccumulatedLosses 2023-06-30 07673770 d:RetainedEarningsAccumulatedLosses 2022-07-01 07673770 c:FRS102 2023-07-01 2024-06-30 07673770 c:AuditExempt-NoAccountantsReport 2023-07-01 2024-06-30 07673770 c:FullAccounts 2023-07-01 2024-06-30 07673770 c:PrivateLimitedCompanyLtd 2023-07-01 2024-06-30 07673770 2 2023-07-01 2024-06-30 07673770 e:PoundSterling 2023-07-01 2024-06-30 iso4217:GBP xbrli:pure

Registered number: 07673770










BIRCHWOOD PHARMA LTD








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 30 JUNE 2024

 
BIRCHWOOD PHARMA LTD
REGISTERED NUMBER: 07673770

BALANCE SHEET
AS AT 30 JUNE 2024

2024
2023
Note
£
£

  

Current assets
  

Debtors: amounts falling due within one year
 4 
219
341

Cash at bank and in hand
 5 
460,072
486,111

  
460,291
486,452

Creditors: amounts falling due within one year
 6 
(1,321)
(1,800)

Net current assets
  
 
 
458,970
 
 
484,652

Total assets less current liabilities
  
458,970
484,652

  

Net assets
  
458,970
484,652


Capital and reserves
  

Called up share capital 
  
110
110

Capital redemption reserve
  
16
16

Profit and loss account
  
458,844
484,526

  
458,970
484,652


The Directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The Directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 16 October 2024.




John Keith Fisher
Director

The notes on pages 3 to 4 form part of these financial statements.

Page 1

 
BIRCHWOOD PHARMA LTD
 

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 JUNE 2024


Called up share capital
Capital redemption reserve
Profit and loss account
Total equity

£
£
£
£


At 1 July 2022
110
16
551,604
551,730


Comprehensive income for the year

Loss for the year
-
-
(67,078)
(67,078)



At 1 July 2023
110
16
484,526
484,652


Comprehensive income for the year

Loss for the year
-
-
(25,682)
(25,682)


At 30 June 2024
110
16
458,844
458,970


The notes on pages 3 to 4 form part of these financial statements.

Page 2

 
BIRCHWOOD PHARMA LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

1.


General information

Birchwood Pharma Ltd is a Company limited by shares and registered on England & Wales. Its registered office is Regus House, Victory Way, Admirals Park, Crossways, Dartford, Kent DA2 6QD.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Research and development

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives, which range from 3 to 6 years.
If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

 
2.3

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.4

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.5

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.6

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Page 3

 
BIRCHWOOD PHARMA LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

3.


Employees

2024
2023
£
£

Wages and salaries
13,000
-

13,000
-


The average monthly number of employees, including directors, during the year was 2 (2023 - 2).


4.


Debtors

2024
2023
£
£


Other debtors
101
223

Prepayments and accrued income
118
118

219
341



5.


Cash and cash equivalents

2024
2023
£
£

Cash at bank and in hand
460,072
486,111



6.


Creditors: Amounts falling due within one year

2024
2023
£
£

Trade creditors
121
-

Other creditors
500
500

Accruals and deferred income
700
1,300

1,321
1,800



7.


Commitments under operating leases

The Company had no commitments under non-cancellable operating leases at the balance sheet date.


Page 4